Oncotarget is a journal made to highlight the impact made as far as cancer research and oncology is concerned. From the very beginning, Oncotarget has been the only platform where people can a get a diversity of resources centering on topics like immunology, physiology, aging, age related diseases, stem cell, neuroscience, cell diseases, autophagy, chromosome, pathology, and endocrinology.For your piece to get featured on Oncotarget, it has to be as original as possible. All research work must be backed up by empirical evidence that has gotten tested over time.For years, Oncotarget has concentrated on the field of Oncology, with a particular interest getting placed on cancer and aging.
Thanks to the journal, people, and scientists from all across the globe now have the chance to find useful resources on the two topics mentioned above. With information getting updated on a weekly basis, Oncotarget has become a reliable reference point for most medical researchers. Oncotarget has been able to enjoy much success because of its devoted editors who are none other than Andrei V. Gudkov and Mikhail Blagosklonny.In the seven years that Oncotarget has been in existence, it has enjoyed an unlimited number of views making an average journal impact of close to four. Oncotarget has been able to evolve taking advantage of social media platforms to gain some mileage.
Today, you can easily access Oncotarget through LinkedIn , Google+, Twitter, YouTube, and Facebook. With an impact factor averaging five, it is proof enough that Oncotarget is a much sought after journal, mainly because of relevance and authenticity.It is a diary backed up by highly researched information, from trusted sources like Mikhail Blagosklonny, a researcher renowned for his passion for scrutinizing scientific evidence with an open mind. Seven years down the line, Oncotarget holds much ground and is the most preferred journal as far as medical research is concerned. Any information posted on Oncotarget remains easily accessible, meaning that there is no discrimination whatsoever as to who should access data from the journal. With such an encouraging reputation, Oncotarget holds a promising future, particularly for its readers.